Product
CytoStorm has developed the Inflex System™, an innovative extracorporeal adsorption device designed for emergency detoxification in life-threatening conditions, such as drug overdose, liver coma, and cytokine storms.
Our solution complements existing emergency interventions like Narcan© by not only restoring breathing but also removing toxins, cytokines, and harmful metabolites directly from the bloodstream, thereby stabilizing patients during the critical post-resuscitation phase.
How the Inflex System™ Works
1 – Blood Extraction
Contaminated blood is drawn from patient and directed into system for processing
2 – Apheresis Column
Apheresis Column separates red blood cells, platelets, and white blood cells from plasma.
Red blood cells are returned to patient, ensuring minimal stress
3 – Plasma
Isolated plasma containing toxins and cytokines is directed to Smart Adsorption Column
4 – Inflex Smart Adsorption Column
Toxins, cytokines, and harmful metabolites are selectively removed from plasma
5 – Blood Return
Cleaned plasma is combined with red blood cells, platelets and white blood cells, and returned to patient
An unmet clinical need
Opioid overdose remains one of the leading causes of preventable death worldwide, while liver coma and cytokine storms (e.g., in sepsis or viral infections) represent major challenges in critical care.
- These conditions lead to rapid deterioration, often overwhelming current intensive care approaches.
- There is a lack of fast, targeted solutions capable of detoxifying blood in real time.
Current treatments
Today, interventions are often limited and reactive:
- Drug overdose is treated with naloxone (Narcan©), which restores breathing but does not remove circulating opioids or metabolites.
- Patients with liver coma (also known as hepatic encephalopathy) rely on treatments such as lactulose, rifaximin, or ultimately liver transplantation, approaches that are slow, inconsistent, and resource-intensive.
- Sepsis is managed with broad immunosuppressive therapies, which lack precision and carry significant risks.
These options are delayed, invasive, or insufficient, leaving a dangerous therapeutic gap in the emergency setting.
Development stage
